

CATABASIS PHARMACEUTICALS INC
Form SC 13G/A
January 17, 2019

**SECURITIES
AND
EXCHANGE
COMMISSION
Washington,
D.C. 20549**

**SCHEDULE
13G**

Under the
Securities
Exchange Act of
1934

(Amendment No.
1)*

Catabasis
Pharmaceuticals,
Inc.
(Name of Issuer)

Common Stock,
\$0.001 par value
(Title of Class of
Securities)

14875P206
(CUSIP Number)

December 31,
2018
(Date of event
which requires
filing of this
statement)

Check the
appropriate box
to designate the
rule pursuant to
which this

Schedule 13G is
filed:

- ☐ Rule 13d-1(b)
- ☒ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

(Page 1 of 6
Pages)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 14875P206 13G/A Page 2 of 6 Pages

1	NAMES OF REPORTING PERSONS
2	Empery Asset Management, LP CHECK THE APPROPRIATE BOX IF A MEMBER (b) " " OF A GROUP
3	SEC USE ONLY CITIZENSHIP OR PLACE OF
4	ORGANIZATION
5	Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
6	SOLE VOTING POWER 499,999 shares of Common Stock issuable upon exercise of Warrants
7	SHARED VOTING POWER SOLE DISPOSITIVE POWER
8	SHARED DISPOSITIVE POWER 499,999 shares of Common Stock issuable upon exercise

of Warrants

AGGREGATE
AMOUNT
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON

9

499,999 shares of
Common Stock
issuable upon exercise
of Warrants

CHECK BOX
IF THE
AGGREGATE
AMOUNT IN ..
ROW (9)

10

EXCLUDES
CERTAIN
SHARES
PERCENT OF
CLASS
REPRESENTED BY
AMOUNT IN ROW
(9)

11

0.70% (See Item 4)
TYPE OF
REPORTING
PERSON

12

PN

	United States	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER
		SHARED VOTING POWER
	6	499,999 shares of Common Stock issuable upon exercise of Warrants
	7	SOLE DISPOSITIVE POWER
	8	SHARED DISPOSITIVE POWER
		499,999 shares of Common Stock issuable upon exercise of Warrants

AGGREGATE
AMOUNT
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON

9

499,999 shares of
Common Stock
issuable upon exercise
of Warrants

CHECK BOX
IF THE
AGGREGATE
AMOUNT IN ..
ROW (9)

10

EXCLUDES
CERTAIN
SHARES
PERCENT OF
CLASS
REPRESENTED BY
AMOUNT IN ROW
(9)

11

0.70% (See Item 4)
TYPE OF
REPORTING
PERSON

12

IN

1

NAMES OF
REPORTING
PERSONS

Martin D. Hoe
CHECK
THE
APPROPRIATE
BOX IF A
MEMBER (b) "
OF A
GROUP

2

APPROPRIATE
BOX IF A
MEMBER (b) "
OF A
GROUP

3

SEC USE ONLY
CITIZENSHIP OR
PLACE OF
ORGANIZATION

4

United States
SOLE
VOTING
5 POWER

NUMBER OF
SHARES
BENEFICIALLY 5
OWNED BY
EACH
REPORTING
PERSON WITH

SHARED VOTING POWER

6 499,999 shares of Common Stock issuable upon exercise of Warrants

7 SOLE
 DISPOSITIVE
 POWER

8 SHARED DISPOSITIVE POWER

499,999 shares
of Common
Stock issuable
upon exercise
of Warrants

AGGREGATE
AMOUNT
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON

9

499,999 shares of
Common Stock
issuable upon exercise
of Warrants

CHECK BOX
IF THE
AGGREGATE
AMOUNT IN ..
ROW (9)

10

EXCLUDES
CERTAIN
SHARES
PERCENT OF
CLASS
REPRESENTED BY
AMOUNT IN ROW
(9)

11

0.70% (See Item 4)
TYPE OF
REPORTING
PERSON

12

IN

CUSIP No. 14875P206 13G/A Page 5 of 6 Pages

This Amendment No. 1 (this "Amendment") amends the statement on Schedule 13G filed on June 25, 2018 (the "Original Schedule 13G") and the Original Schedule 13G as amended, the "Schedule 13G"), with respect to shares of Common Stock, \$0.001 par value (the "Common Shares"), of Catabasis Pharmaceuticals, Inc. (the "Company"). Capitalized terms used herein and not otherwise defined in this Amendment have the meanings set forth in the Schedule 13G. This Amendment amends and restates Items 2(e), 4 and 5 in their entirety as set forth below.

Item 2(e). CUSIP NUMBER:

14875P206

Item 4. OWNERSHIP.

The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 71,038,419 shares of Common Stock issued and outstanding on October 31, 2018, as represented in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2018 and assumes the exercise of the Company's reported warrants (the "Reported Warrants").

The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all shares of Common Stock underlying the Reported Warrants held by the Empery Funds. Each of the Reporting Individuals, as Managing Members of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all shares of Common Stock underlying the Reported Warrants held by the Empery Funds. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person. Each of the Empery Funds and the Reporting Individuals hereby disclaims any beneficial ownership of any such shares of Common Stock.

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]

CUSIP No. 14875P206 13G/A Page 6 of 6 Pages

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

DATED: January 17, 2019

EMPERY ASSET
MANAGEMENT,
LP
By: EMPERY AM
GP, LLC, its General
Partner

By: /s/ Ryan M. Lane
Name: Ryan M.
Lane
Title: Managing
Member

/s/ Ryan M. Lane
Ryan M. Lane

/s/ Martin D. Hoe
Martin D. Hoe